Lara Sullivan - Apr 14, 2022 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Chief Executive Officer, Director
Signature
/s/ Pamela Connealy, Attorney-in-Fact for Lara Sullivan
Stock symbol
PYXS
Transactions as of
Apr 14, 2022
Transactions value $
$0
Form type
4
Date filed
4/15/2022, 07:56 PM
Previous filing
Apr 4, 2022
Next filing
Jan 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PYXS Common Stock Award $0 +315K +30.28% $0.00 1.36M Apr 14, 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date.
F2 The Compensation Committee also approved a grant to the Reporting Person, effective January 3, 2023, of an additional 95,684 RSUs that vest on April 13, 2023, subject to the Reporting Person's continued employment through the grant and vesting dates.
F3 The Compensation Committee also approved a grant to the Reporting Person of $200,000 cash compensation that is payable in full on April 13, 2023, subject to the Reporting Person's continued employment through the payment date.